Known globally for his industry research and expertise, Dr. Wallach will help to drive new areas of research and product development at Mind Cure
VANCOUVER, BC, Oct. 7, 2020 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce the addition of Dr. Jason Wallach to the company’s scientific advisory board. Highly regarded for his work in both drug development and pharmacological research, Dr. Wallach has a PhD in Pharmacology and Toxicology from University of the Sciences (Philadelphia, PA), where he currently teaches in the Department of Pharmaceutical Sciences as well as the Substance Use Disorders Institute.
Dr. Wallach is joining Mind Cure’s scientific advisory board and will advise on research and drug discovery across the nootropic and psychedelic spectrum. “I am a believer in the potential to treat the mental health illnesses of today in novel ways with new medicines,” said Dr. Wallach. “Mind Cure is putting together an impressive team of researchers, scientists and industry leaders. I look forward to working together with them and collaborating on new ways to treat mental health.”
“We are building our operations to be completely rooted in science,” said Philip Tapley, Chairman, President, and CEO. “By aligning with world-class scientists and researchers like Dr. Wallach, we will ensure that our operations, from research to product development, are driven by science and data first. Dr. Wallach’s impeccable track record and specific industry experience puts him in the position to choose to work with anyone. We are honoured he chose Mind Cure and welcome him to the team with excitement.”
Mind Cure believes that the mental health space is ready for transformation, and that innovation and investment will lead to a major disruption in how mental health is treated. Mind Cure intends to further its investigation into new product candidates and treatments which are effective in treating mental health. These new product candidates range from nootropics, psychoactive products, and psychedelic substances.
About Jason Wallach
Dr. Jason Wallach is an instructor in the Department of Pharmaceutical Sciences as well as the Substance Use Disorders Institute at the University of the Sciences (Philadelphia, PA). He also holds an adjunct appointment at Cooper Medical School of Rowan University (Camden, NJ) and is an author on over 20 publications in peer-reviewed journal articles as well as numerous book chapters and popular press articles. Dr. Wallach has always been fascinated by how drugs could alter a person’s reality and have a lasting impact. Now he and his team spend time in the lab researching how existing drugs, including psychoactive and dissociative drugs, and new formulations can best help patients.
Dr. Wallach has a PhD in Pharmacology and Toxicology from University of the Sciences and a BS in Cell and Molecular Biology from Indiana University of Pennsylvania.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.
On Behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward- looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Dr. Wallach advising on research and drug discovery across the nootropic and psychedelic spectrum, and collaborating on new ways to treat mental health; Mind Cure’s intention to build its operations rooted in science and ensure that its operations are driven by science and data first; Mind Cure’s belief that the mental health space is ready for transformation, and that innovation and investment will lead to a major disruption in how mental health is treated; Mind Cure’s intention to further its investigation into new product candidates and treatments which are effective in treating mental health, and the range of those product candidates; and Mind Cure’s mission to identify, develop and commercialize products that ease suffering, increase productivity and enhance mental health.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; the addition of Dr. Wallach will help Mind Cure on research and drug discovery across the nootropic and psychedelic spectrum; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the addition of Dr. Wallach may not help Mind Cure’s research and drug discovery across the nootropic and psychedelic spectrum; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.
For further information: Investor Relations: firstname.lastname@example.org; 1-888-593-8995